Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Hepatocellular 6Solid Cancers 2Melanoma 2Advanced NSCLC 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Lung Neoplasms 1Immune-related Adverse Event 1Esophageal Squamous Cell Carcinoma 1EBV-associated Tumors 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 2Immune Checkpoint Inhibitors 2aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Advanced NSCLC × Immune Checkpoint Inhibitors × Clear all
NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡